Cambridge, UK-based Alchemab Therapeutics has raised £60m ($82m) in a Series A funding round, in a bid to advance its target-agnostic drug discovery platform.
Clinical stage company NewAmsterdam Pharma (NAP) has raised $196m (€160m) through Series A funding round to support the full Phase III development of its ApoB and LDL-c lowering small molecule drug, obicetrapib.
Austria-based OncoOne closed its Series A funding round with €13m raised. This financing will be used to officially launch the company and support the development of oncology treatments...